Sage Journals: Discover world-class research

Abstract

Keywords

Multiple sclerosis rebound disease treatment sequencing disease-modifying therapies dimethyl fumarate fingolimod

Get full access to this article

View all access options for this article.

References

Sorensen

Koch-Henriksen

Petersen

et al . Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014; 261(6): 1170–1177.

Larochelle

Metz

Lécuyer

et al . Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler 2017; 23(1): 72–81.

Havla

Pellkofer

Meinl

et al . Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012; 69(2): 262–264.

Berger

Baumgartner

Rauer

et al . Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol 2015; 282: 118–122.

Giordana

Cavalla

Uccelli

et al . Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. Mult Scler 2018; 24: 1133–1137.

Harmel

Schlunk

Harms

Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl-fumarate: A case report. Mult Scler 2018; 24: 1131–1133.

Chen

Assmann

Krenz

et al . Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 2014; 124(5): 2188–2192.

Loewe

Holnthoner

Groger

et al . Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168(9): 4781–4787.

Rebound disease in multiple sclerosis

Abstract

Keywords

Get full access to this article

References